[A contribution to the rate of side-effects of hepatotropic contrast media. A clinical comparative study of iodoxamate (Endomirabil) and ioglycamid (Bilivistan) (author's transl)]. / Beitrag zur Nebenwirkungsrate hepatotroper Kontrastmittel. Klinische Vergleichsuntersuchung von Iodoxamat (Endomirabil) und Ioglycamid (Bilivistan)
Radiologe
; 17(2): 70-3, 1977 Feb.
Article
en De
| MEDLINE
| ID: mdl-322198
The new substance Iodoxamate (Endomirabil) is a hepatotropic contrast medium. In a clinical comparative study, the contrast of the biliary ducts and gall bladder is equivalent compared with Ioglycamid (Bilivistan). Assuming equal conditions of injection and in conformity with animal experimental studies, the rate of side effects of Iodoxamate is distinctly lower than that of the referring substance Iolgycamid (Bilivistan).
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Ácidos Triyodobenzoicos
/
Yodobenzoatos
/
Ácido Yoglicámico
Tipo de estudio:
Diagnostic_studies
/
Evaluation_studies
Límite:
Humans
Idioma:
De
Revista:
Radiologe
Año:
1977
Tipo del documento:
Article
Pais de publicación:
Alemania